<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913103</url>
  </required_header>
  <id_info>
    <org_study_id>CLSG-MCL-POLA</org_study_id>
    <nct_id>NCT04913103</nct_id>
  </id_info>
  <brief_title>Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL</brief_title>
  <acronym>CLSGMCLPOLA</acronym>
  <official_title>A Phase II, Open-label Study of Polatuzumab-vedotin (PV) in Combination With Bendamustine and Rituximab for Patients With Mantle Cell Lymphoma, Who Relapse After Previous Therapy With Bruton Tyrosine Kinase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Czech Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Czech Lymphoma Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in&#xD;
      combination with bendamustine and rituximab for patients with mantle cell lymphoma, who&#xD;
      relapse after previous therapy with Bruton tyrosine kinase inhibitor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      Efficacy: to evaluate the efficacy of the combination of polatuzumab vedotin plus&#xD;
      bendamustine and rituximab (BR) with respect to progression-free survival (PFS)&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Efficacy: to evaluate the efficacy of polatuzumab vedotin plus BR with respect to secondary&#xD;
      efficacy endpoints, namely overall response rate, duration of response, event free survival&#xD;
      and overall survival; Safety objective; Exploratory objectives&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label, single arm, combination - polatuzumab vedotine + rituximab+bendamustin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>evaluation of the efficacy of the combination of polatuzumab vedotin plus bendamustine and rituximab (BR) with respect to progression-free survival (PFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>4 years</time_frame>
    <description>efficacy of polatuzumab vedotin plus BR with respect to overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DoR)</measure>
    <time_frame>4 years</time_frame>
    <description>efficacy of PV plus BR with respect to duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event free survival (EFS)</measure>
    <time_frame>4 years</time_frame>
    <description>efficacy of PV plus BR with respect to event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>efficacy of PV plus BR with respect to overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Lymphoma, Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>single arm, open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of polatuzumab-vedotin, bendamustine and rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab vedotin</intervention_name>
    <description>treatment by a study drug polatuzumab-vedotin, i.v.</description>
    <arm_group_label>single arm, open-label</arm_group_label>
    <other_name>Polivy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride</intervention_name>
    <description>treatment by a study drug bendamustin i.v.</description>
    <arm_group_label>single arm, open-label</arm_group_label>
    <other_name>Bendamustine Accord</other_name>
    <other_name>Bendamustine Glenmark</other_name>
    <other_name>Bendamustine KABI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>treatment by a study drug rituximab, i.v.</description>
    <arm_group_label>single arm, open-label</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>Rixathon</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written Informed Consent Form&#xD;
&#xD;
          -  Adult patients with relapsed or refractory MCL after failure of BTK&#xD;
             inhibitor-containing therapy (e.g. ibrutinib, acalabrutinib, zanubrutinib)&#xD;
&#xD;
          -  Patients previously treated with bendamustine are eligible for the study treatment, in&#xD;
             the case they had achieved objective response (CR or PR) and the last dose of&#xD;
             bendamustine was administered ≥ 1 year before the estimated study treatment initiation&#xD;
             date (C1D1)&#xD;
&#xD;
          -  Tumor tissue at the lymphoma relapse after failure of BTK inhibitor. In case that a&#xD;
             re-biopsy is not possible (e.g. urgent need to start study treatment), archival tissue&#xD;
             blocks may be used to confirm the diagnosis&#xD;
&#xD;
          -  Bone marrow examination by standard trephine biopsy including flow cytometry analysis&#xD;
             within 8 weeks before study entry&#xD;
&#xD;
          -  Age 18-80 years at the time of signing Informed Consent Form&#xD;
&#xD;
          -  ECOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy ≥ 2 months&#xD;
&#xD;
          -  Adequate hematologic function (unless due to underlying disease, as established for&#xD;
             example, by extensive bone marrow involvement or due to hypersplenism secondary to the&#xD;
             involvement of the spleen by MCL per the investigator), defined as follows:&#xD;
&#xD;
               -  Hemoglobin ≥ 80g/L&#xD;
&#xD;
               -  ANC ≥ 1,500/μL&#xD;
&#xD;
               -  Platelet count ≥ 75,000/μL Enrollment of patients with lower counts is possible&#xD;
                  only after consulting the medical monitor.&#xD;
&#xD;
          -  Adequate cardiac functions according to echocardiography (ECHO) within 6 months before&#xD;
             study entry&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods that result in a failure rate&#xD;
             of &lt; 1% per year during the treatment period and for at least 12 months after the last&#xD;
             dose of study treatment. Women must refrain from donating eggs during this same&#xD;
             period. A woman is considered to be of childbearing potential if she is&#xD;
             post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of&#xD;
             amenorrhea with no identified cause other than menopause), and has not undergone&#xD;
             surgical sterilization (removal of ovaries and/or uterus). The definition of&#xD;
             childbearing potential may be adapted for alignment with local guidelines or&#xD;
             requirements.&#xD;
&#xD;
        Examples of contraceptive methods with a failure rate of &lt; 1% per year include bilateral&#xD;
        tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation,&#xD;
        hormone-releasing intrauterine devices, and copper intrauterine devices.&#xD;
&#xD;
        The reliability of sexual abstinence should be evaluated in relation to the duration of the&#xD;
        clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence&#xD;
        (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are&#xD;
        not acceptable methods of contraception.&#xD;
&#xD;
          -  For women of childbearing potential, a negative serum pregnancy test result within 7&#xD;
             days prior to commencement of dosing. Women who are considered not to be of&#xD;
             childbearing potential are not required to have a pregnancy test.&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             a condom, and agreement to refrain from donating sperm, as defined below:&#xD;
&#xD;
        With female partners of childbearing potential or pregnant female partners, men must remain&#xD;
        abstinent or use a condom during the treatment period and for at least 5 months after the&#xD;
        last dose of polatuzumab vedotin, 3 months after the last dose of rituximab, and for at&#xD;
        least 6 months after the last dose of bendamustine to avoid exposing the embryo for the&#xD;
        duration of the pregnancy. Men must refrain from donating sperm during this same period.&#xD;
        The reliability of sexual abstinence should be evaluated in relation to the duration of the&#xD;
        clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence&#xD;
        (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not&#xD;
        acceptable methods of preventing drug exposure. Male patients considering preservation of&#xD;
        fertility should bank sperm before study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior organ transplantation&#xD;
&#xD;
          -  Current Grade ≥ 2 peripheral neuropathy by clinical examination or demyelinating form&#xD;
             of Charcot-Marie-Tooth disease&#xD;
&#xD;
          -  History of other malignancy that could affect compliance with the protocol or&#xD;
             interpretation of results Patients with a history of curatively treated basal or&#xD;
             squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix at&#xD;
             any time prior to the study are eligible Patients with any malignancy appropriately&#xD;
             treated with curative intent and the malignancy has been in remission without&#xD;
             treatment for ≥ 2 years prior to enrollment are eligible Patients with low-grade,&#xD;
             early-stage prostate cancer (Gleason score 6 or below, Stage&#xD;
&#xD;
             1 or 2) with no requirement for therapy at any time prior to study are eligible.&#xD;
&#xD;
          -  Evidence of significant, uncontrolled, concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results.&#xD;
&#xD;
          -  Recent major surgery (e.g. within 4 weeks prior to the start of Cycle 1), other than&#xD;
             for diagnosis&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection&#xD;
             (excluding fungal infections of nail beds) at study enrollment or significant&#xD;
             infections within 2 weeks before the start of Cycle 1.&#xD;
&#xD;
          -  Clinically significant liver disease, including active viral or other hepatitis,&#xD;
             current alcohol abuse, or cirrhosis&#xD;
&#xD;
          -  Illicit drug or alcohol abuse within 12 months prior to screening, in the&#xD;
             investigator's judgment&#xD;
&#xD;
          -  Any of the following abnormal laboratory values (unless any of these abnormalities are&#xD;
             due to underlying lymphoma):&#xD;
&#xD;
        INR &gt; 1.5 x upper limit of normal (ULN) in the absence of therapeutic anticoagulation aPTT&#xD;
        &gt; 1.5 x ULN in the absence of a lupus anticoagulant&#xD;
&#xD;
          -  Serum AST and ALT &gt; 3 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt; 2 x ULN Patients with documented Gilbert disease may be enrolled if&#xD;
             total bilirubin is &gt; 3.0 x ULN.&#xD;
&#xD;
          -  Serum creatinine clearance &lt; 40 mL/min (using Cockcroft-Gault formula or creatinine&#xD;
             levels assessed directly from the collected urine)&#xD;
&#xD;
          -  Patients with suspected active or latent tuberculosis (as confirmed by a positive&#xD;
             interferon-gamma release assay)&#xD;
&#xD;
          -  Positive test results for chronic hepatitis B infection defined as positive hepatitis&#xD;
             B surface antigen (HBsAg) serology&#xD;
&#xD;
          -  Patients with occult or prior hepatitis B infection defined as positive total&#xD;
             hepatitis B core antibody and negative HBsAg may be included if hepatitis B virus&#xD;
             (HBV) DNA is undetectable at the time of screening. These patients must be willing to&#xD;
             undergo regular DNA testing and appropriate antiviral therapy as indicated.&#xD;
&#xD;
          -  Positive test results for hepatitis C virus (HCV) antibody serology testing Patients&#xD;
             positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is&#xD;
             negative for HCV RNA.&#xD;
&#xD;
          -  Known history of HIV seropositive status&#xD;
&#xD;
          -  Patients with a history of progressive multifocal leukoencephalopathy&#xD;
&#xD;
          -  Pregnancy or lactation or intending to become pregnant during study&#xD;
&#xD;
          -  CNS lymphoma In patients with clinical signs attributable to CNS lymphoma, CT scan&#xD;
             (MRI also acceptable) of the head and examination of cerebrospinal fluid will be&#xD;
             required prior to study treatment initiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Klener, Prof.MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Czech Lymphoma Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pavel Klener, prof.MD,PhD</last_name>
    <phone>+420224962568</phone>
    <email>pavel.klener2@vfn.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marketa Petrova, Ing.</last_name>
    <phone>+420224962676</phone>
    <email>petrova@lymphoma.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrea Janíková, AssProfMDPhD</last_name>
      <phone>+420532 233 642</phone>
      <email>janikova.andrea@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>David Belada, Ass.prof.MD</last_name>
      <phone>+420 495 832 866</phone>
      <email>david.belada@fnhk.cz</email>
    </contact>
    <contact_backup>
      <last_name>Martin Šimkovič</last_name>
      <email>martin.simkovic@fnhk.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Aleš Obr., MD,Ph.D.</last_name>
      <phone>+420 588 442 790</phone>
      <email>ales.obr@fnol.cz</email>
    </contact>
    <contact_backup>
      <last_name>Vít Procházka, Prof.MD,PhD.</last_name>
      <email>vit.prochazka@fnol.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Juraj Ďuraš, MD</last_name>
      <phone>+420 597 372 754</phone>
      <email>juraj.duras@fno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzeň</name>
      <address>
        <city>Plzeň</city>
        <zip>323 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Kateřina Steinerová, MD</last_name>
      <phone>+420 377 103 722</phone>
      <email>steinerovak@fnplzen.cz</email>
    </contact>
    <contact_backup>
      <last_name>Tomáš Procházka, MD</last_name>
      <email>prochazkat@fnplzen.cz</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Heidi Mocikova, MD,PhD</last_name>
      <phone>+420 267 163 554</phone>
      <email>heidi.mocikova@fnkv.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles University General Hospital</name>
      <address>
        <city>Prague 2</city>
        <zip>12800</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Pavel Klener, prof.MD,PhD</last_name>
      <phone>+420224962568</phone>
      <email>pavel.klener2@vfn.cz</email>
    </contact>
    <contact_backup>
      <last_name>Marek Trněný, prof.MD,CSc.</last_name>
      <phone>+4202249622527</phone>
      <email>trneny@cesnet.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory/relapsed mantle cell lymphoma</keyword>
  <keyword>polatuzumab-vedotin</keyword>
  <keyword>bendamustine</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

